EXTON, Pa., April 25 /PRNewswire-FirstCall/ -- ViroPharma Incorporated announced today that abstracts regarding HCV-796, an orally dosed non-nucleoside viral polymerase inhibitor with the potential to interfere with the replication of hepatitis C virus that is being co-developed with Wyeth Pharmaceuticals, a division of Wyeth , will be presented at two upcoming scientific meetings: the 2006 European Association for the Study of the Liver (EASL) meeting, to be held this week in Vienna, Austria (April 26th to 30th, 2006), and at the 2006 Digestive Disease Week (DDW) meeting, to be held in Los Angeles, California (May 20th to 25th, 2006). The abstract contents are available on the EASL (http://www.easl.ch/easl2006) and DDW (http://www.ddw.org) web sites.
Abstract at EASL:
Safety and pharmacokinetics of the non-nucleoside polymerase inhibitor, HCV-796: Results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects. Chandra P, Raible D, Moyer L, Harper D, Speth J, Villano S, Fruncillo R
Abstract at DDW:
Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in patients with chronic hepatitis C virus: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple-dose study. Chandra P, Raible D, Harper D, Speth J, Villano S, Bichier G
HCV-796 is an investigational non-nucleoside polymerase inhibitor compound for the treatment of hepatitis C that is being evaluated in ongoing clinical trials in combination with PEG-Interferon by ViroPharma and Wyeth. In previously disclosed results from the phase 1b study of HCV-796 as a monotherapy, the patient cohort with the highest exposure to the compound achieved a peak mean HCV viral load reduction of 1.4 log10, or 96 percent, on day four of a 14-day dosing period. HCV-796 was found to be generally well tolerated, with favorable pharmacokinetics and no dose-limiting toxicities. Mild to moderate headache was the most frequent adverse event reported overall. There were no treatment-emergent serious adverse events.
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company’s website at http://www.viropharma.com.
ViroPharma Incorporated
CONTACT: Will Roberts, Director, Corporate Communications, ViroPharmaIncorporated, +1-610-321-6288
